Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1953 1
1954 2
1961 1
1964 1
1965 2
1966 2
1967 3
1968 2
1969 11
1970 4
1971 10
1972 5
1973 5
1974 13
1975 9
1976 7
1977 19
1978 13
1979 18
1980 16
1981 18
1982 20
1983 27
1984 29
1985 30
1986 24
1987 30
1988 27
1989 34
1990 33
1991 30
1992 40
1993 41
1994 39
1995 37
1996 57
1997 39
1998 39
1999 58
2000 61
2001 64
2002 86
2003 108
2004 100
2005 103
2006 106
2007 90
2008 78
2009 86
2010 121
2011 132
2012 138
2013 134
2014 154
2015 175
2016 171
2017 166
2018 158
2019 177
2020 206
2021 193
2022 153
2023 145
2024 141
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,654 results

Results by year

Filters applied: . Clear all
Page 1
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. Among authors: shimada y. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Wilke H, et al. Among authors: shimada y. Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17. Lancet Oncol. 2014. PMID: 25240821 Clinical Trial.
Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.
Kato M, Shiosakai M, Kuwahara K, Iba K, Shimada Y, Saito M, Isogai Y, Sekine D, Aoki K, Koga N, Higuchi T. Kato M, et al. Among authors: shimada y. Psychiatry Clin Neurosci. 2024 Feb;78(2):113-122. doi: 10.1111/pcn.13615. Epub 2023 Dec 1. Psychiatry Clin Neurosci. 2024. PMID: 37933521 Free PMC article. Clinical Trial.
Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.
Luo H, Ikenaga N, Nakata K, Higashijima N, Zhong P, Kubo A, Wu C, Tsutsumi C, Shimada Y, Hayashi M, Oyama K, Date S, Abe T, Ideno N, Iwamoto C, Shindo K, Ohuchida K, Oda Y, Nakamura M. Luo H, et al. Among authors: shimada y. J Exp Clin Cancer Res. 2024 Sep 11;43(1):258. doi: 10.1186/s13046-024-03178-6. J Exp Clin Cancer Res. 2024. PMID: 39261943 Free PMC article.
Oncofetal IGF2BP3-mediated control of microRNA structural diversity in the malignancy of early-stage lung adenocarcinoma.
Fujiwara Y, Takahashi RU, Saito M, Umakoshi M, Shimada Y, Koyama K, Yatabe Y, Watanabe SI, Koyota S, Minamiya Y, Tahara H, Kono K, Shiraishi K, Kohno T, Goto A, Tsuchiya N. Fujiwara Y, et al. Among authors: shimada y. Proc Natl Acad Sci U S A. 2024 Sep 3;121(36):e2407016121. doi: 10.1073/pnas.2407016121. Epub 2024 Aug 28. Proc Natl Acad Sci U S A. 2024. PMID: 39196622
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).
Aokage K, Koyama S, Kumagai S, Nomura K, Shimada Y, Yoh K, Wakabayashi M, Fukutani M, Furuya H, Miyoshi T, Tane K, Samejima J, Taki T, Hayashi T, Matsubayashi J, Ishii G, Nishikawa H, Ikeda N, Tsuboi M. Aokage K, et al. Among authors: shimada y. Clin Cancer Res. 2024 Dec 16;30(24):5584-5592. doi: 10.1158/1078-0432.CCR-24-1561. Clin Cancer Res. 2024. PMID: 39453771 Clinical Trial.
3,654 results